Peng, Z., Li, C., Wang, X., Zhang, Y., Yang, L., Huang, X., Deng, T., Lu, L., Zong, H., Zhang, J., Sun, M., Cai, D., Ye, F., Deng, W., Jin, Y., Ying, J., Liu, J., Feng, D., Fang, J., Shen, L. (2026). Disitamab vedotin (DV) plus toripalimab (Tor) and chemotherapy (Chemo)/trastuzumab (Tra) for first-line (1L) HER2-expressing locally advanced or metastatic (la/m) gastric cancer (GC): Updated results from the RC48-C027 trial.. Journal of Clinical Oncology. https://doi.org/10.1200/jco.2026.44.17_suppl.lba4026